E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression

British Journal of Dermatology

Volumn 169, Issue 3, 2013, Pages 618-628

  Lade Keller, J ^a   Riber Hansen, R ^a   Guldberg, P ^b   Schmidt, H ^a   Hamilton Dutoit, S J ^a   Steiniche, T ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; NERVE CELL ADHESION MOLECULE; PARAFFIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UVOMORULIN;

ADULT; ARTICLE; CANCER GROWTH; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY;

CADHERINS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; OBSERVER VARIATION; PTEN PHOSPHOHYDROLASE; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84883343415     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12426     Document Type: Article

References (37)

1. Makrilia N, Kollias A, Manolopoulos L, Syrigos K,. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest 2009; 27: 1023-37.
2. Berx G, van Roy F,. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009; 1: a003129.
3. Johnson JP,. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999; 18: 345-57.
4. Andersen K, Nesland JM, Holm R, et al,. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 2004; 17: 990-7.
5. Kreizenbeck GM, Berger AJ, Subtil A, et al,. Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 949-58.
6. Tang A, Eller MS, Hara M, et al,. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J Cell Sci 1994; 107: 983-92.
7. Hsu MY, Wheelock MJ, Johnson KR, Herlyn M,. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1996; 1: 188-94.
8. Hsu M, Andl T, Li G, et al,. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci 2000; 113: 1535-42.
9. Herlyn M, Berking C, Li G, Satyamoorthy K,. Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. Melanoma Res 2000; 10: 303-12.
10. Li G, Satyamoorthy K, Herlyn M,. Dynamics of cell interactions and communications during melanoma development. Crit Rev Oral Biol Med 2002; 13: 62-70.
11. Derycke LD, Bracke ME,. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 2004; 48: 463-76.
12. Bosserhoff AK, Ellmann L, Kuphal S,. Melanoblasts in culture as an in vitro system to determine molecular changes in melanoma. Exp Dermatol 2011; 20: 435-40.
13. Hsu MY, Meier FE, Nesbit M, et al,. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000; 156: 1515-25.
14. Li G, Satyamoorthy K, Herlyn M,. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001; 61: 3819-25.
15. Bachmann IM, Straume O, Puntervoll HE, et al,. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 2005; 11: 8606-14.
16. Rickelt S, Franke WW, Doerflinger Y, et al,. Subtypes of melanocytes and melanoma cells distinguished by their intercellular contacts: heterotypic adherens junctions, adhesive associations, and dispersed desmoglein 2 glycoproteins. Cell Tissue Res 2008; 334: 401-22.
17. Hao L, Ha JR, Kuzel P, et al,. Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail. Br J Dermatol 2012; 166: 1184-97.
18. Bryan RT, Tselepis C,. Cadherin switching and bladder cancer. J Urol 2010; 184: 423-31.
19. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ,. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 1999; 147: 631-44.
20. Hazan RB, Phillips GR, Qiao RF, et al,. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 2000; 148: 779-90.
21. Cavallaro U, Schaffhauser B, Christofori G,. Cadherins and the tumour progression: is it all in a switch? Cancer Lett 2002; 176: 123-8.
22. Nishizawa A, Nakanishi Y, Yoshimura K, et al,. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. Cancer 2005; 103: 1693-700.
23. Tucci MG, Lucarini G, Brancorsini D, et al,. Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol 2007; 157: 1212-16.
24. Sansal I, Sellers WR,. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-63.
25. Guldberg P, thor Straten P, Birck A, et al,. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997; 57: 3660-3.
26. Wu H, Goel V, Haluska FG,. PTEN signaling pathways in melanoma. Oncogene 2003; 22: 3113-22.
27. Di Cristofano A, Pandolfi PP,. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-90.
28. Mikhail M, Velazquez E, Shapiro R, et al,. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 2005; 11: 5153-7.
29. Slipicevic A, Holm R, Nguyen MT, et al,. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol 2005; 124: 528-36.
30. Davies MA, Stemke-Hale K, Lin E, et al,. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 2009; 15: 7538-46.
31. Balch CM, Buzaid AC, Soong SJ, et al,. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
32. Jensen TO, Riber-Hansen R, Schmidt H, et al,. Tumor and inflammation markers in melanoma using tissue microarrays: a validation study. Melanoma Res 2011; 21: 509-15.
33. Whiteman DC, Zhou XP, Cummings MC, et al,. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer 2002; 99: 63-7.
34. Zhou XP, Gimm O, Hampel H, et al,. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 2000; 157: 1123-8.
35. Silye R, Karayiannakis AJ, Syrigos KN, et al,. E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol 1998; 186: 350-5.
36. Haluska FG, Tsao H, Wu H, et al,. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006; 12: 2301s-7s.
37. Shull AY, Latham-Schwark A, Ramasamy P, et al,. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS ONE 2012; 7: e43369.